Abstract Session 6: Immune

Co-Chair(s)

• 

  Eileen Boyle, MD PhD

  Principal Clinical Research Fellow
  UCL Cancer Institute
  London, United Kingdom
• 

  Fanghuang Zhan, MD & PhD (he/him/his)

  Professor
  University of Arkasas Medical Sciences
  Little Rock, Arkansas, United States

Presentations:

• 4:30 PM – 4:42 PM EEST

  OA-32: The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma
  

  Speaker: Brian A. Walker, PhD (he/him/his) – Indiana University
• 4:42 PM – 4:54 PM EEST

  OA-02: α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells
  

  Speaker: Jessica Encinas Mayoral (she/her/hers) – Fundación Investigación Biomédica Hospital 12 de Octubre
• 4:54 PM – 5:06 PM EEST

  OA-09: Combination of forimtamig with standard of care improves depth and duration of response in preclinical models of multiple myeloma
  

  Speaker: Aintzane Zabaleta, PhD (she/her/hers) – CIMA (Pamplona)
• 5:06 PM – 5:18 PM EEST

  OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients
  

  Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
• 5:18 PM – 5:30 PM EEST

  OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
  

  Speaker: Ross S. Firestone, MD/PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, New York City NY, USA